Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease
1. CNM-Au8 shows improvements in mitochondrial health relevant to Parkinson's disease. 2. Study results support continued development of CNM-Au8 for PD treatment. 3. Recent findings indicate significant metabolic restoration in PD neurons. 4. Safety data indicates no toxicity for CNM-Au8 in treated cells. 5. Collaborative research enhances CNM-Au8's therapeutic potential for neurodegenerative disorders.